Real-World Burden of Nonalcoholic Steatohepatitis

• DOI: 10.1016/j.cgh.2020.06.064
• Publication Date: 2020-07-04T06:23:49Z
• Authors: Andreas Geier; Mary E. Rinella; Maria-Magdalena Balp; Sarah Jane McKenna; Clifford A. Brass; Raymond Przybysz; Jennifer Cai; Amanda Knight; Meghan Gavaghan; Tanya Howe; Daniel Rosen; Vlad Ratziu
• Keywords: Nonalcoholic steatohepatitis; Steatohepatitis

Background & AimsNonalcoholic steatohepatitis (NASH) is associated with an increase in healthcare resource use and poor health-related quality of life (HRQoL). We assessed the humanistic economic burden NASH, disease management, patient journey.MethodsWe performed a cross-sectional analysis data, collected from July through November 2017, Growth Knowledge Disease Atlas Real-World Evidence program, reported by physicians United States, France, Germany. extracted demographic medical data records. Some patients voluntarily completed survey that provided information on history, treatment satisfaction, patient-reported outcomes.ResultsWe analyzed 1216 (mean age, 54.9±12.3 years; 57.5% male; mean body mass index, 31.7±6.9); 64.6% had biopsy-confirmed NASH comorbidities were recorded for 41.3%. Treatments included lifestyle modification (64.6%) or statins (25.0%), vitamin E (23.5%), metformin (20.2%). Patients more physician (4.5 vs 3.7) outpatient visits (1.8 vs1.4) than suspected not confirmed biopsy. Among 299 who survey, 47.8% various symptoms to their NASH. Symptomatic significantly lower HRQoL without symptoms.ConclusionsIn 3 countries, we found be regular resources; reduced HRQoL. The appears underestimated. Studies are needed determine fibrosis stage severity. Nonalcoholic journey. outcomes. symptoms. In